FDA Approves Two New DHE Migraine Treatments for Fast Relief

Two innovative DHE-based migraine treatments just earned FDA approval—offering some Americans new options for managing attacks. Molly O'Brien has details in this #MigraineMinute News Update. Read More: https://bit.ly/4kgmXMt and https://bit.ly/3SYet0c *DHE is not safe for the management of hemiplegic migraine, migraine with brainstem aura, in people with certain comorbidities, or in those who take certain medications. Script: Many Americans with migraine now have two new treatment options, thanks to recent FDA approvals of Brekiya and Atzumi. Both drugs utilize Dihydroergotamine or DHE. While DHE for migraine has been around for decades, these two new drugs have new delivery methods. Brekiya is the first and only DHE auto-injector approved for the acute treatment of migraine and cluster headache in adults.  Atzumi is the first and only DHE nasal powder approved for the acute treatment of migraine with or without aura in adults. It's important to note that DHE has several safety implications and contraindications and must be prescribed by a healthcare provider.